Clinical trials
Breast clinical trials
Below are recruiting breast clinical trials, each written for real people, not researchers. We’re tracking 2,625 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07653893Recruiting
T-DXd for breast cancer that has spread to the brain
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07646171Recruiting
Everolimus After Alpelisib for Advanced Breast Cancer
This trial tests a drug called everolimus in women with hormone receptor-positive metastatic breast cancer who have already tried alpelisib (a PI3K inhibitor) combined with hormone therapy. The goal is to see if this next treatment can help control cancer growth.
Tel AvivAges 21 years+ - NCT06690645Recruiting
Stress and breast cancer treatment response
This trial studies how psychological stress might affect the success of pre-surgery breast cancer treatments (neoadjuvant therapy). If you are about to start treatment and have never had cancer therapy before, this study could help doctors understand your response better.
Shenyang, LiaoningAges 18 years+ - NCT03971045RecruitingPhase 2
Pembrolizumab plus low-dose oral chemo for chest wall breast cancer
This Phase 2 trial tests pembrolizumab (an immune therapy) plus low-dose oral cyclophosphamide in people with chest wall breast cancer that has spread locally and may have distant metastases. It aims to see if this combination can shrink tumors and control cancer longer, especially in tumors with certain immune markers.
MilanAges 18 years+ - NCT07630935Recruiting
Breast Cancer Risk Check for Night Shift Workers
This study helps women who work night shifts understand their personal breast cancer risk and get personalized advice to stay healthy. Researchers will review your health history and work schedule to create a customized care plan.
ParisAges 18 years+ - NCT07630402Recruiting
Heart Imaging Study for Women With Early Breast Cancer
This study helps doctors find the best way to monitor heart health in women with HER2-positive breast cancer who are receiving a type of targeted chemotherapy. The goal is to catch any heart problems early and keep you safe during treatment.
Rochester, New YorkAges 18–79 - NCT07635342RecruitingPhase 2
Pyrotinib plus trastuzumab and chemotherapy for HER2-positive early breast cancer
This trial tests a combination of three drugs—pyrotinib, trastuzumab, and chemotherapy—to treat HER2-positive breast cancer that has not been treated before. HER2 is a protein found on some cancer cells; blocking it may help stop the cancer from growing.
Shijiazhuang, HebeiAges 18–65 - NCT06452706RecruitingPhase 2
Study of TQB2102 for HER2-negative breast cancer that has spread
This study tests a new drug, TQB2102, for people with HER2-negative breast cancer that has spread and no longer responds to standard treatments. The goal is to see if the drug can shrink tumors or slow the cancer.
Bozhou, AnhuiAges 18–75 - NCT07629206Recruiting
Freezing therapy for small, early-stage breast cancer
This study tests whether freezing a small breast tumor (cryoablation) is a safe and effective treatment option for older adults with early-stage, hormone-receptor-positive breast cancer. Instead of surgery, the goal is to destroy the tumor by freezing it in place.
Glendale, CaliforniaAges 70 years+ - NCT06693024Recruiting
Neratinib after standard therapy for HER2-positive early breast cancer
This trial is testing whether adding neratinib after standard treatment helps prevent HER2-positive early breast cancer from coming back. It is open only to patients treated at Peking University People's Hospital.
Beijing, Beijing MunicipalityAges Any age - NCT06693037Recruiting
Choosing next treatment after incomplete response in HER2+ breast cancer
This trial looks at the best next treatment for women with HER2-positive breast cancer who still have leftover cancer after surgery and standard pre-surgery treatment. It helps doctors choose the right therapy for you.
Beijing, Beijing MunicipalityAges Any age - NCT07624617Recruiting
Fasting and Breast Cancer Treatment Study
This study looks at whether periods of fasting (eating for shorter time windows) might help improve how well a breast cancer medication called capivasertib works. You'll wear a glucose monitor, track your food, and follow fasting schedules while continuing your regular cancer treatment.
Minneapolis, MinnesotaAges 18 years+ - NCT06587789Recruiting
Ribociclib plus hormone therapy for high-risk breast cancer
This trial tests adding ribociclib (a targeted pill) to standard hormone therapy for people with early but high-risk HR-positive, HER2-negative breast cancer, after surgery.
Hangzhou, ZhejiangAges 18–80 - NCT06698679Recruiting
Plasma markers and breast cancer risk & treatment
This study looks at substances in your blood (metabolites) to see if they are linked to breast cancer risk, how well treatment works, and long-term outcomes. It has three groups: women without breast cancer, newly diagnosed patients getting standard therapy, and those who have finished treatment.
Shenyang, LiaoningAges 18 years+ - NCT06222879RecruitingPhase 1/Phase 2
New drug combinations for advanced breast cancer
This trial tests a combination of new drugs (HRS-8080, SHR-A2009, or others) for people with advanced breast cancer that has stopped responding to previous treatments. The goal is to see if these combinations can shrink tumors or slow the cancer's growth.
Changsha, HunanAges 18–75 - NCT06538896RecruitingPhase 2
Tislelizumab and nab-paclitaxel for advanced triple-negative breast cancer with bone spread
This trial tests a combination of two drugs, tislelizumab (an immunotherapy) and nab-paclitaxel (a chemotherapy), as the first treatment for advanced triple-negative breast cancer that has spread to the bones. It aims to see if this combination can help shrink or control the cancer.
Hangzhou, ZhejiangAges 18–70 - NCT06536608Recruiting
Oketani breast massage for breastfeeding help
This study tests a special breast massage technique (Oketani massage) to see if it helps new moms breastfeed more easily. If you are a healthy first-time mom in your 36th week of pregnancy, you may be able to join.
ÇankırıAges 18–45 - NCT07617025Recruiting
Understanding Breast Cancer Subtypes in BRCA Carriers
This study examines how different molecular subtypes (patterns of genes and proteins) of breast cancer behave in people with BRCA1 or BRCA2 mutations. By studying tumor samples and medical records, researchers hope to better predict which treatments will work best and predict long-term outcomes for BRCA-positive breast cancer patients.
GenovaAges 18 years+ - NCT07616440Recruiting
Ultrasound drug delivery with chemotherapy for HER2-positive breast cancer
This study tests a new technique that uses focused ultrasound to deliver cancer drugs directly to breast tumors, combined with standard chemotherapy. The goal is to improve treatment effectiveness for HER2-positive breast cancer before surgery.
Hangzhou, ZhejiangAges 18–70 - NCT07616258Recruiting
Reducing follow-up visits after breast cancer treatment
This study tests whether some patients who finished curative breast cancer treatment can safely have fewer follow-up appointments and scans. Researchers want to see if less frequent monitoring is safe for patients without any signs of cancer returning.
Beaumont, DublinAges 18 years+ - NCT07615751RecruitingPhase 3
New drug combination for advanced HER2-positive breast cancer
This trial tests whether a newer drug called dalpiciclib works better than chemotherapy when combined with two other anti-HER2 drugs (pyrotinib and trastuzumab) for advanced breast cancer that has spread. The goal is to find a treatment that works well with fewer side effects.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07614620Recruiting
Hypnosis to reduce anxiety and chemo side effects in young cancer patients
This study tests whether hypnosis (a relaxed, focused mental state) can help young people with sarcoma, germ cell tumors, or breast cancer manage anxiety and reduce side effects from chemotherapy. The trial takes place at Institut Bergonié in France.
BordeauxAges 15–49 - NCT07616453RecruitingPhase 2
New Drug Plus Hormone Therapy for Hormone-Responsive Breast Cancer
This trial tests whether a new drug called culmerciclib, combined with hormone therapy, works better than hormone therapy alone for early-stage breast cancer that grows quickly and responds to estrogen. The goal is to shrink tumors before surgery and improve outcomes.
Hangzhou, ZhejiangAges 18–75 - NCT07616427RecruitingPhase 2
New drug plus hormone therapy for HER2-positive breast cancer
This study tests a new drug called fovinaciclib combined with hormone therapy and HER2-targeting drugs for early-stage breast cancer that has specific markers (HR-positive and HER2-positive). The goal is to shrink tumors before surgery and improve outcomes.
Nanjing, JiangsuAges 18–75
Hear when a new Breast trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for breast?
- Yes. Clin2 currently lists 2,625 recruiting breast studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a breast trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a breast trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.